Stocks & Investing
Stocks and Investing
Stocks and Investing
Tue, August 10, 2021
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Salveen Richter Downgraded (BLUE) to Hold and Decreased Target to $23 on, Aug 10th, 2021
Salveen Richter of Goldman Sachs, Downgraded "bluebird bio, Inc." (BLUE) to Hold and Decreased Target from $63 to $23 on, Aug 10th, 2021.
Salveen has made no other calls on BLUE in the last 4 months.
There are 2 other peers that have a rating on BLUE. Out of the 2 peers that are also analyzing BLUE, all agree with Salveen's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- Matthew Harrison of "Morgan Stanley" Maintained at Hold with Decreased Target to $35 on, Friday, July 16th, 2021
- Yun Zhong of "Berenberg" Downgraded from Strong Buy to Hold and Held Target at $35 on, Thursday, July 1st, 2021
